These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19596350)

  • 1. [Medical and economic evaluation of new peritoneal dialysis solutions].
    Ryckelynck JP; Lobbedez T; Ficheux M; Chatelet V; Thuillier-Lecouf A; Henri P; Hurault de Ligny B
    Nephrol Ther; 2009 Jun; 5 Suppl 4():S286-9. PubMed ID: 19596350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel peritoneal dialysis solutions--what are the clinical implications?
    Jörres A
    Blood Purif; 2012; 33(1-3):153-9. PubMed ID: 22269466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low GDP Solution and Glucose-Sparing Strategies for Peritoneal Dialysis.
    Szeto CC; Johnson DW
    Semin Nephrol; 2017 Jan; 37(1):30-42. PubMed ID: 28153193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new peritoneal dialysis solutions: friends only, or foes in part?
    ter Wee PM; van Ittersum FJ
    Nat Clin Pract Nephrol; 2007 Nov; 3(11):604-12. PubMed ID: 17957197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on peritoneal dialysis solutions.
    García-López E; Lindholm B; Davies S
    Nat Rev Nephrol; 2012 Feb; 8(4):224-33. PubMed ID: 22349485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Icodextrin and peritoneal dialysis: advantages and new applications.
    Dousdampanis P; Musso CG; Trigka K
    Int Urol Nephrol; 2018 Mar; 50(3):495-500. PubMed ID: 28674854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial.
    Takatori Y; Akagi S; Sugiyama H; Inoue J; Kojo S; Morinaga H; Nakao K; Wada J; Makino H
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1337-44. PubMed ID: 21493740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel "bimodal" use of icodextrin peritoneal dialysis solutions.
    Burkart J
    Kidney Int; 1998 Apr; 53(4):1089-90. PubMed ID: 9551423
    [No Abstract]   [Full Text] [Related]  

  • 9. [Influence of new dialysis solutions on clinical results in patients treated with peritoneal dialysis].
    Haag-Weber M
    Wien Klin Wochenschr; 2005; 117 Suppl 6():89-97. PubMed ID: 16437339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritoneal dialysis solutions: nutritional aspects.
    Gokal R
    Perit Dial Int; 1997; 17 Suppl 3():S69-72. PubMed ID: 9304667
    [No Abstract]   [Full Text] [Related]  

  • 11. Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions.
    Han SH; Ahn SV; Yun JY; Tranaeus A; Han DS
    Am J Kidney Dis; 2009 Oct; 54(4):711-20. PubMed ID: 19619922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nutritional effects of increasing dialysis dose by adding an icodextrin daytime dwell to Nocturnal Intermittent Peritoneal Dialysis (NIPD) in children.
    van Hoeck KJ; Rusthoven E; Vermeylen L; Vandesompel A; Marescau B; Lilien M; Schroder CH
    Nephrol Dial Transplant; 2003 Jul; 18(7):1383-7. PubMed ID: 12808177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical considerations when prescribing icodextrin: a narrative review.
    Silver SA; Harel Z; Perl J
    Am J Nephrol; 2014; 39(6):515-27. PubMed ID: 24925229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of icodextrin on patient survival and technique success in patients undergoing peritoneal dialysis.
    Han SH; Ahn SV; Yun JY; Tranaeus A; Han DS
    Nephrol Dial Transplant; 2012 May; 27(5):2044-50. PubMed ID: 21968011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of neutral-pH, low-glucose degradation product peritoneal dialysis solutions compared with standard solutions: a secondary analysis of the balANZ Trial.
    Howard K; Hayes A; Cho Y; Cass A; Clarke M; Johnson DW
    Am J Kidney Dis; 2015 May; 65(5):773-9. PubMed ID: 25746151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost savings from peritoneal dialysis therapy time extension using icodextrin.
    Johnson DW; Vincent K; Blizzard S; Rumpsfeld M; Just P
    Adv Perit Dial; 2003; 19():81-5. PubMed ID: 14763039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
    Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
    Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of using icodextrin as a starting therapy for peritoneal permeability].
    Fernández-Reyes MJ; Bajo MA; del Peso G; Olea T; Sánchez-Villanueva RL; González E; Heras M; Sánchez R; Selgas R
    Nefrologia; 2009; 29(2):130-5. PubMed ID: 19396318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The peritoneal-renal syndrome.
    Nessim SJ; Bargman JM
    Nat Rev Nephrol; 2013 May; 9(5):302-6. PubMed ID: 23507827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Biocompatible" Neutral pH Low-GDP Peritoneal Dialysis Solutions: Much Ado About Nothing?
    Misra PS; Nessim SJ; Perl J
    Semin Dial; 2017 Mar; 30(2):164-173. PubMed ID: 28251697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.